Lonza

How are we investing to keep up with the needs of drug developers? Two of our leaders at Lonza recently talked to PHARMAnetwork about what Lonza is doing to help our customers bring their therapies to life. "2024 has been an exciting year for investments and growth at Lonza so far. Within Biologics, we continue to invest in building out our end-to-end offering to ensure that we can serve our customers across the entire lifecycle of a drug, from early development to commercial manufacture," said Jean-Christophe Hyvert, President of Biologics at Lonza. "With the increasing complexity of small molecule APIs coupled with a continued demand for commercial manufacture, we are committed to strengthening our capacity and capabilities for manufacturing molecules requiring complex chemistry and facing solubility and bioavailability issues," said Gordon Bates, President of Small Molecules at Lonza. Read the full interview here: https://lnkd.in/dEpfBNwH #AHealthierWorld #PharmaceuticalManufacturing #Biologics #SmallMolecules #Growth

Immunogenicity poses a critical risk to all biologics, including monoclonal antibodies, ADCs, recombinant proteins, cell & gene therapies, and mRNA-based therapies. The consequences can endanger patients and reduce treatment effectiveness. In this webinar, Noel Smith, Head of Immunology, will explore how a cutting-edge, high-sensitivity in vitro immunopeptidomics assay (MHC-Associated Peptide Proteomics or "MAPPs") can identify regions within therapeutic proteins prone to HLA binding. This helps assess the sequence-based risk of activating a T cell response, a key factor in preclinical immunogenicity risk assessments. Join us in collaboration with The Antibody Society on Thursday, 21st November 2024, for an opportunity to learn how this advanced assay can support a more informed and proactive approach to immunogenicity risk assessment in biologics development.  Register here: https://lnkd.in/e2xK3wHp

Thank you to everyone who joined us in person for our first-ever UK Bites & Insights event! 🎉 It was a fun half-day filled with engaging presentations from our SMEs, Christoph Aellig and Casey Jager, and a valuable networking lunch where attendees connected with other industry peers and the Lonza Small Molecules team—including William McFarlane, our dedicated contact for the UK region. 🤝 If you missed it, catch the highlights! 🎥 Watch our wrap-up video to see the insights and connections from the event. https://bit.ly/4hFdRYH And for those who couldn’t attend, you can still meet William at upcoming UK conferences: * Biotech Outsourcing Strategies Manchester: 26th - 27th November * Drug Delivery to the Lungs Conference (DDL) Edinburgh: 11th - 13th December Let’s keep the conversation going - see you there! #LonzaSM #Networking #BitesAndInsights #UKEvents #PharmaNetworking #WeWorkAsOne

This morning, we announced an investment in additional bioconjugation capabilities in Visp (CH). The expansion will add two multipurpose 1,200L manufacturing suites and manufacturing-related infrastructure to the existing bioconjugation facility in Visp for launch and commercial supply. The new suites will double Lonza’s multipurpose capacity for the launch and commercial supply of bioconjugates. The flexible multi-customer suites are designed to run the increasingly complex and variable processes needed to manufacture antibody-drug conjugates (ADCs) and other bioconjugates maturing through the drug pipeline. As part of Lonza’s emission reduction strategy, the manufacturing suites follow sustainability design standards for new builds that include energy-efficient water heating systems, air supply and lighting solutions, leading to a significant decrease in carbon footprint compared to traditional design solutions. In addition, technology for improved cytotoxic liquid waste management will reduce waste by up to 90%. Read more here: https://lnkd.in/dHV78kM2 #AHealthierWorld #Expansion #Growth #Biologics #PharmaceuticalManufacturing

🏆 Winner: Lonza is 𝗕𝗲𝘀𝘁 𝗖𝗗𝗠𝗢 at World ADC! We're absolutely thrilled and humbled to accept the award for Best CDMO at this year's World ADC in San Diego. Big thanks to the World ADC Event Series and our tireless ADC team for making this happen.

Bringing a biologic to market is more than ticking boxes – it’s a high-stakes strategy. Join our experts, Yves SCHEURER and Robin Schumacher, in a webinar to explore the interplay between regulatory affairs, process development, and manufacturing in Microbial biopharmaceutical commercialization.   📅 Date: Thursday, 21 November ⏰ Time: 11 am EST | 8 am PST | 5 pm CET 🔗 Register here: https://lnkd.in/dNVUR5SS   In this session, gain insights into: •    Best practices for integrating regulatory affairs with process development. •    Approaches to streamline manufacturing while maintaining quality •    Strategies for accelerating commercialization timelines   Perfect for professionals in regulatory, manufacturing, and process development looking to ensure robust drug quality throughout commercialization. #Biopharma #Webinar #DrugDevelopment #Bioprocessing #QualityAssurance #LonzaBio

Join us for an insightful webinar on "Linking Rational Design and Material-Sparing Strategies for Enabled Intermediates and Their Drug Products," on Tuesday, November 19, 2024, at 11:00 AM EST | 5:00 PM CET. Discover how Lonza is addressing bioavailability challenges in poorly soluble molecules through material-sparing techniques and advanced methodologies. Our experts will cover key strategies, including small-scale spray drying, compaction simulation, ASAP Prime, PBPK modelling, and salt/co-crystal creation. Dive into the science—join our experts live! Featured Speakers: 🔹 Hannah Worrest, Manager, Bioavailability Enhancement Engineering 🔹 Bailey Coker, Bioavailability Enhancement Engineer 🔹 Dr. Allison DuRoss, Manager, Bioavailability Enhancement Engineering Register now (https://lnkd.in/dbRF8z8q) to secure your spot! #Bioavailability #LonzaSM #SmallMolecules #WeWorkAsOne #FormulationDevelopment

We're looking forward to attending the AAEV conference starting this week. We have a great presentation on day 2 featuring our R&D expert, Vijetha Bhat. 🎤 A Platform Approach For Producing Engineered Extracellular Vesicles • Monday,11 November • 16:20 • Vijetha Bhat, Manager, Research & Development, Licensing See you there!

Synaffix BV, a Lonza company focused on the development of antibody-drug conjugates, has just licensed its ADC technology to BigHat Biosciences. Under the terms of the agreement, BigHat will receive target-specific access to Synaffix’s late-clinical stage, site-specific ADC technology platform, which enables the transformation of antibodies into proprietary, best-in-class ADC products. Jean-Christophe Hyvert, President of Biologics at Lonza, commented: “We are pleased to announce this collaboration with BigHat for its next-gen ADC molecule, which shows how drug developers can benefit from a fully integrated suite of services across our Biologics division. The Lonza network has continued to adapt to the evolving ADC landscape, including the recent addition of a highly potent vial fill capability at our Stein (CH) facility. This dedicated ADC drug product capacity expansion completes our offer for comprehensive, end-to-end development and manufacturing services for ADCs, simplifying the path from DNA-to-IND and beyond for our customers.” Read more here: https://lnkd.in/d5uU4KfX #AHealthierWorld #ADCs #PharmaceuticalManufacturing #DrugDevelopment #Biologics

Join us at the 2024 Oregon Bioengineering Symposium on November 15 at Oregon Health & Science University. If you’re attending, make sure to stop by our stand and say hello! Our experts, John Baumann and Tyler Gist are looking forward to discussing your small molecule drug development challenges and how we can help you achieve your project objectives. #LonzaSM #WeWorkAsOne #DrugDevelopment